Diabetic macular edema

Developments in Ophthalmology

Volumn 54, Issue , 2014, Pages 164-173

  Patelli, Fabio ^a   Radice, Paolo ^b   Giacomotti, Enrico ^a  

^a Radiology Department IGEA Clinic   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; MACULAR EDEMA; PROCEDURES; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

DIABETIC RETINOPATHY; HUMANS; LASER COAGULATION; MACULAR EDEMA; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 84929517489     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000360463     Document Type: Article

References (71)

1. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type I diabetes. Ophthalmology 2009; 116: 497-503
2. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-2664
3. Knudsen ST, Bek T, Poulsen PL, Hove MN, Rehling M, Mogensen CE. Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care 2002; 25: 2328-2334
4. Rotsos TG, Moschos MM. Cystoid macular edema. J Clin Ophthalmol 2008; 2: 919-930
5. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010; 88: 279-291
6. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kBdependent fashion. J Clin Invest 1998; 101: 1905-1915
7. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
8. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006; 19: 335-344
9. Miyamoto N, De Kozak Y, Jeanny JC, et al. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 2007; 50: 461-470
10. Cai W, Rook SL, Jiang ZY, Takahara N, Aiello LP. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Invest Ophthalmol Vis Sci 2000; 41: 1885-1893
11. Puliafito CA, Hee MR, Lin CP, et al. Imaging of macular disease with optical coherence tomography. Ophthalmology 1995; 102: 217-229
12. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999; 127: 688-693
13. Yamamoto S, Yamamoto T, Hayashi M, et al. Morphological and functional analysis of diabetic macular edema by optical coherence tomography and multifocal electroretinograms. Graefes Arch Clin Ophthalmol 2001; 239: 96-101
14. Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, et al. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002; 43: 1588-1594
15. Kim BY, Smith SD, Kaiser PK. Optical coherence tomography patterns of diabetic macular edema. Am J Ophthalmol 2006; 142: 405-412
16. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806
17. Lee C, Olk R. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 1991; 98: 1594-1602
18. Javey G, Schwartz SG, Flynn HW Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res 2012; 2102: 548732
19. Diabetic retinopathy clinical research network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867
20. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): 12-month data. Report 2. Ophthalmology 2010; 117: 1078-1086
21. Rosenfeld PR, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 335: 1419-1431
22. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 335: 1432-1444
23. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112
24. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retina vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133
25. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405
26. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151
27. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997; 16: 398-406
28. Patelli F, Fasolino G, Radice P, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macula edema with and without previous macular laser treatment. Retina 2005; 25: 840-845
29. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317
30. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923
31. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116: 2175-2181
32. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614
33. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625
34. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114
35. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor trap-eye in patients with diabetic macular oedema. Br J Ophthalmol 2009; 93: 144-149
36. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2004; 242: 630-637
37. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy of diffuse nontractional diabetic macular edema. Retina 2008; 28: 420-426
38. Ikeda T, Sato K, Katano T, Hayashi Y. Vitrectomy for cystoid macular edema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol 1999; 83: 12-14
39. La Heij EC, Hendrikse F, Kessels AGH, Derhaag PJFM: Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 2001; 239: 264-270
40. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-759
41. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology 1988; 95: 1335-1339
42. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214-219
43. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130: 178-186
44. Stefansson E, Landers MB 3rd, Wolbarsht ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc 1981; 79: 307-334
45. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001; 132: 369-377
46. Nguyen QD, Shah SM, Van Anden E, et al. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004; 45: 617-624
47. Stefansson E, Landers MB 3rd, Wolbarsht ML. Vitrectomy, lensectomy, and ocular oxygenation. Retina 1982; 2: 159-166
48. Hosford GE, Olson DM. Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am J Physiol Lung Cell Physiol 2003; 285:L161-L168
49. Kadonosono K, Itoh N, Ohno S. Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema. Am J Ophthalmol 2000; 130: 740-744
50. Van Effenterre G, Guyot-Argenton C, Guiberteau B, Hany I, Lacotte JL. Macular edema caused by contraction of the posterior hyaloid in diabetic retinopathy. Surgical treatment of a series of 22 cases (in French). J Fr Ophthalmol 1993; 16: 602-610
51. Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003; 135: 169-177
52. Kumagai K, Furukawa M, Ogino N, Larson E, Iwaky M, Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009; 29: 464-472
53. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomized controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol 2005; 89: 81-86
54. Shah SP, Patel M, Thomas D, Aldington S, Laidlaw DA. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br J Ophthalmol 2006; 90: 33-36
55. Kojima T, Terasaki H, Nomura H, et al. Vitrectomy for diabetic macular edema: effect of glycemic control (HbA(1c)), renal fuction (creatinine) and other local factors. Ophthalmic Res 2003; 35: 192-198
56. Stefaniotou M, Aspiotis M, Kalogeropoulos C, et al. Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal. Eur J Ophthalmol 2004; 14; 137-143
57. Parolini B, Panozzo G, Gusson E, et al. Diode laser, vitrectomy and intravitreal trimcinolone. A comparative study for the treatment of diffuse non-tractional diabetic macular edema. Semin Ophthalmol 2004; 19: 1-12
58. Kralinger MT, Pedri M, Kralinger F, Troger J, Kieselbach GF. Long-term outcome after vitrectomy for diabetic macular edema. Ophthalnologica 2006; 220: 147-152
59. Yamamoto T, Takeuchi S, Sato Y, Yamashita H. Long-term follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn J Ophthalmol 2007; 51: 285-291
60. Shimonagano Y, Makiuchi R, Miyazaki M, Doi N, Uemura A, Sakamoto T. Results of visual acuity and foveal thickness in diabetic macular edema after vitrectomy. Jpn J Ophthalmol 2007; 51: 204-209
61. Goebel W, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina 2002; 22: 759-767
62. Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology 1992; 99: 58-62
63. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214-219
64. Otani T, Kishi S. Tomographic findings of foveal hard exudates in diabetic macular edema. Am J Ophthalmol 2001; 131: 50-54
65. Wakabayashi T, Fujiwara M, Sakaguchi H, Kusaka S, Oshima Y. Foveal microstructure and visual acuity in surgically closed macular holes: spectral-domain optical coherence tomographic analysis. Ophthalmology 2010; 117: 1815-1824
66. Sakamoto A, Nishijima K, Kita M, Oh H, Tsujikawa A, Yoshimura N. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1325-1330
67. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004; 45: 2399-2406
68. Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 2010; 30: 774-780
69. Fernández EJ, Povazay B, Hermann B, et al. Three-dimensional adaptive optics ultrahigh-resolution optical coherence tomography using a liquid crystal spatial light modulator. Vision Res 2005; 45: 3432-3444
70. Schmitz-Valckenberg S, Fleckenstein M, Göbel AP, Hohman TC, Holz FG. Optical coherence tomography and autofluorescence findings in areas with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52: 1-6
71. Cho M, Witmer MT, Favarone G, Chan RP, D'Amico DJ, Kiss S. Optical coherence tomography predicts visual outcome in macula-involving rhegmatogenous retinal detachment. Clin Ophthalmol 2012; 6: 91-96